Business Context and Reporting Period
This Form 8-K, filed on March 23, 2021, by AmerisourceBergen Corporation (now Cencora, Inc.), discloses financial information regarding its pending acquisition of the majority of Walgreens Boots Alliance, Inc.'s (WBA) Alliance Healthcare wholesale distribution businesses and certain retail pharmacy operations. The transaction, announced on January 6, 2021, involves a purchase price of approximately $6.5 billion.
Key Financial Metrics
The filing provides financial data for the target business (Alliance Healthcare) rather than the consolidated results of AmerisourceBergen. Specific metrics for the target business are contained in the attached exhibits:
- Transaction Value: Approximately $6.5 billion total consideration.
- Payment Structure: $6.275 billion in cash (subject to adjustments) and 2 million shares of Company common stock.
- Target Financial Statements:
- Audited statements for years ended August 31, 2020, and 2019 (Exhibit 99.1).
- Unaudited condensed statements for the three months ended November 30, 2020, and 2019 (Exhibit 99.2).
- Pro forma combined statements as of December 31, 2020 (Exhibit 99.3).
Note: This filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity for either the target or the combined entity; these figures are located in the referenced exhibits.
Material Changes
The primary material change is the execution of the Share Purchase Agreement to acquire Alliance Healthcare. This represents a significant strategic expansion into the European wholesale distribution market and specific retail pharmacy operations. The filing incorporates pro forma financial information to illustrate the combined entity's financial position as if the acquisition had occurred on December 31, 2020, though it explicitly states these do not represent actual historical results.
Guidance, Outlook, and Risks
Outlook and Management Commentary: The pro forma financial information is presented for informational purposes only and is not intended to project future results. Management emphasizes that the combined businesses may not achieve the results indicated in the pro forma data.
Risks and Contingencies: The filing includes an extensive list of risk factors that could cause actual results to differ materially from expectations, including:
- Failure to obtain regulatory approvals for the acquisition.
- Integration challenges, including difficulty, time, and cost.
- Unfavorable trends in pharmaceutical pricing and reimbursement rates.
- Legal proceedings, including opioid litigation and government enforcement actions.
- Impact of COVID-19 on operations, payment terms, and customer/supplier solvency.
- Failure to achieve anticipated synergies.
Investor Verification Checklist
- Review Exhibit 99.1 for the audited financial performance of Alliance Healthcare for the fiscal years ended August 31, 2020, and 2019.
- Examine Exhibit 99.2 for the unaudited condensed financial results of Alliance Healthcare for the quarter ended November 30, 2020.
- Analyze Exhibit 99.3 to understand the pro forma impact of the acquisition on AmerisourceBergen's balance sheet and operations.
- Verify the status of regulatory approvals required to consummate the $6.5 billion transaction.
- Assess the specific purchase price adjustment mechanisms and the valuation of the 2 million shares of common stock included in the deal.